We are live on
!
Find out more
HM
HealthCor Management Portfolio holdings
AUM
$109M
1-Year Est. Return
10.64%
This Fund
S&P 500
This Quarter
Est. Return
-8.51%
1 Year Est. Return
+10.64%
3 Year Est. Return
+50.22%
5 Year Est. Return
+140.3%
10 Year Est. Return
–
AUM
$995M
AUM Growth
-$504M
(-34%)
Cap. Flow
-$395M
Cap. Flow
% of AUM
-39.65%
Top 10 Holdings %
Top 10 Hldgs %
49.03%
Holding
79
New
15
Increased
11
Reduced
25
Closed
21
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HOLX
Hologic
HOLX
|
+$29.9M |
| 2 |
Cigna
CI
|
+$24.9M |
| 3 |
Eli Lilly
LLY
|
+$21.2M |
| 4 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$18.3M |
| 5 |
Intuitive Surgical
ISRG
|
+$17M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Envista
NVST
|
+$44.5M |
| 2 |
AbbVie
ABBV
|
+$41.2M |
| 3 |
Teleflex
TFX
|
+$35.2M |
| 4 |
Abbott
ABT
|
+$32.4M |
| 5 |
CVS Health
CVS
|
+$29M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.68% |
| 2 | Financials | 0.12% |
| 3 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Biogen
BIIB
$30.7B
| $84.4M | 8.48% |
413,640
+11,980
| +3% | +$2.45M |
|
|
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $72.1M | 7.24% |
903,850
+193,740
| +27% | +$18.3M |
|
3
Boston Scientific
BSX
$68.4B
| $67.4M | 6.77% |
1,807,990
-42,460
| -2% | -$1.73M |
|
4
BioMarin Pharmaceuticals
BMRN
$11.7B
| $61.4M | 6.17% |
740,948
-28,068
| -4% | -$2.23M |
|
5
Centene
CNC
$30.1B
| $45.8M | 4.6% |
540,860
-93,750
| -15% | -$7.79M |
|
6
UnitedHealth
UNH
$383B
| $35M | 3.52% |
68,230
-4,350
| -6% | -$2.18M |
|
7
Natera
NTRA
$38.6B
| $31.8M | 3.2% |
898,420
-551,116
| -38% | -$20.4M |
|
8
Bristol-Myers Squibb
BMY
$132B
| $31.8M | 3.19% |
412,420
-117,740
| -22% | -$8.97M |
|
9
LivaNova
LIVN
$4.45B
| $30.4M | 3.05% |
486,550
-15,800
| -3% | -$1.12M |
|
|
HOLX
10
DELISTED
Hologic
HOLX
| $27.9M | 2.8% |
+402,110
| New | +$29.9M |
|
11
Tenet Healthcare
THC
$21.8B
| $27.3M | 2.74% |
518,990
+235,260
| +83% | +$16.4M |
|
|
CCXI
12
DELISTED
ChemoCentryx, Inc.
CCXI
| $27.2M | 2.73% |
1,097,370
+140,630
| +15% | +$3.1M |
|
13
Elevance Health
ELV
$81.6B
| $26.2M | 2.63% |
54,230
-19,120
| -26% | -$9.46M |
|
|
14
Cigna
CI
$76.1B
| $25.4M | 2.55% |
+96,470
| New | +$24.9M |
|
15
Danaher
DHR
$138B
| $24.6M | 2.47% |
109,281
-688
| -0.6% | -$158K |
|
|
16
Eli Lilly
LLY
$1.03T
| $22.9M | 2.3% |
+70,630
| New | +$21.2M |
|
17
Cencora
COR
$60.7B
| $22.2M | 2.23% |
156,910
-174,000
| -53% | -$26.6M |
|
18
Humana
HUM
$44B
| $22.1M | 2.22% |
47,220
-61,820
| -57% | -$27.5M |
|
|
19
Abbott
ABT
$183B
| $21.7M | 2.18% |
199,300
-285,440
| -59% | -$32.4M |
|
|
RVNC
20
DELISTED
Revance Therapeutics, Inc.
RVNC
| $19.6M | 1.97% |
1,418,088
-5,337
| -0.4% | -$82.2K |
|
21
Henry Schein
HSIC
$9.7B
| $19.1M | 1.92% |
248,920
-6,310
| -2% | -$529K |
|
22
Cytokinetics
CYTK
$10.9B
| $19.1M | 1.92% |
485,600
-649,510
| -57% | -$26.1M |
|
|
23
CALL
Boston Scientific
BSX
$68.4B
| $18.6M | 1.87% |
+500,000
| New | +$20.4M |
|
|
SGEN
24
DELISTED
Seagen Inc. Common Stock
SGEN
| $18.2M | 1.83% |
+103,060
| New | +$14.9M |
|
25
Incyte
INCY
$24.9B
| $17.8M | 1.79% |
234,130
-266,270
| -53% | -$20.2M |
|
Similar funds
IA
EPC
TCMV
SI
HCWM
PC
RF
AWM
HealthCor Management's Q2 2022 Portfolio in Review
As of Q2 2022, HealthCor Management held 79 positions worth $995M, down 34% from $1.5B the previous quarter. Its ten largest holdings account for 49% of the portfolio.
HealthCor Management withdrew a net $395M in Q2 2022, closing 21 positions and reducing 25 holdings. Its most notable exit was Envista, an estimated $44.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 92% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, HealthCor Management opened a new position in Hologic worth $27.9M.
- HealthCor Management's largest Q2 2022 buy was Hologic: 402,110 shares worth $27.9M.
- HealthCor Management added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2022, an estimated $18.3M increase.
- HealthCor Management's biggest Q2 2022 reduction was Abbott, cutting an estimated $32.4M.
- HealthCor Management fully exited Envista in Q2 2022, selling an estimated $44.5M.
- HealthCor Management's ten largest holdings make up 49% of its $995M portfolio in Q2 2022.
- HealthCor Management opened 15 new positions and closed 21 in Q2 2022.
- HealthCor Management's portfolio value fell 34% quarter-over-quarter to $995M.
Based on HealthCor Management's 13F filing for Q2 2022, filed 15 Aug 2022.